NCT00924911已完成1 期
A Two Part Single Dose, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations, Drug Interaction and Food Effect on an GSK1322322 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- GSK1322322 Blood PK as described in the protocol
研究概览
简要总结
Part 1 of this study will assess the relative bioavailability of GSK1322322 administered as one of three investigational tablets compared to powder in a bottle formulation. Pharmacokinetics of these three tablets will be evaluated and the investigation tablet with the optimal PK profile will be progressed to Part 2. In Part 2 the investigational tablet selected from Part 1 will be coadministered with food alone, an H2 blocker alone, or an H2 blocker given in combination with ascorbic acid to evaluate the effect on GSK1322322 pharmacokinetics. Plasma GSK1322322 PK profile, safety, and tolerability will be assessed from each dose group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject is healthy.
- •Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- •A female is eligible to enter and participate in this study if she is of Non-childbearing potential
- •Male subjects must agree to use one of the contraception methods listed in the protocol Body weight greater than or equal to 50 kg and body mass index between 18.5-29.9 kg/m2 inclusive.
- •Capable of giving written informed consent
- •QTcB less than 450 msec; or QTc less than 480 msec in subjects with Bundle Branch Block on Screening ECG.
- •AST, ALT, alkaline phosphatase and bilirubin less than or equal to 1.5xULN (isolated bilirubin greater than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%)
排除标准
- •The subject has a positive pre-study drug/alcohol screen.
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •A positive test for HIV antibody.
- •History of regular alcohol consumption within 6 months of the study defined in the protocol.
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Exposure to more than four new chemical entities within 12 months prior to the dosing day.
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- •Pregnant females as determined by positive human chorionic gonadotropin test at screening or prior to dosing.
- •Lactating females.
- •Subjects who have asthma or a history of asthma within the past 6 months.
- •History of smoking or history of regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
- •Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos, satsuma, ugli, tangerine, and tangelo, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication
研究组 & 干预措施
Part 1
Experimental
A 4 way crossover of three GSK1322322 tablet formulations and GSK1322322 powder in bottle
干预措施: GSK1322322 (Drug)
Part 2
Experimental
A 3 way crossover of a GSK1322322 tablet with a high fat meal, with Ranitidine, and with Ranitidine and Vitamin C.
干预措施: GSK1322322 (Drug)
结局指标
主要结局
GSK1322322 Blood PK as described in the protocol
时间窗: 48 hours
次要结局
- Safety parameters including adverse events, clinical laboratory tests, concomitant medications, electrocardiograms, and vital signs.(48 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy SubjectsInfections, BacterialNCT00896558GlaxoSmithKline52
已完成
1 期
GSK1349572 First Time in Human StudyHealthy SubjectsNCT00555035GlaxoSmithKline20
已完成
1 期
A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male SubjectsInflammatory Bowel DiseasesNCT02302404GlaxoSmithKline79
已完成
1 期
Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in AdultsInfluenzaNCT00510874GlaxoSmithKline780
已完成
1 期
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic ImpairmentHepatitis BNCT04971928GlaxoSmithKline24